Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:946019.
doi: 10.5402/2012/946019. Epub 2012 Oct 14.

Inflammatory malignant fibrous histiocytoma associated with leukemoid reaction or leukocytosis: a comprehensive review

Affiliations

Inflammatory malignant fibrous histiocytoma associated with leukemoid reaction or leukocytosis: a comprehensive review

Jorge Hurtado-Cordovi et al. ISRN Oncol. 2012.

Abstract

Inflammatory malignant fibrous histiocytoma (IMFH) associated with leukemoid reaction (LR)/leukocytosis is a rare entity. In this paper, we search PubMed for all known cases of IMFH associated with LR/leukocytosis in an attempt to draw conclusions about this variant's response to treatments and its pathophysiology. Medline electronic database was searched using key words such as malignant fibrous histiocytoma, leukemoid reaction, and leukocytosis. A total of 16 patients were found, twelve males (75%) and 4 female (25%), with a mean age of 62.6 years, ranging from 47 to 77. The mean survival was 770 days, ranging from 14 to 6570 days. Four patients were alive at last follow-up: 6570 days, 1095 days, 335 days, and 180 days, respectively. Of the 12 patients that expired, death occurred approximately 92 days after the onset of LR or leukocytosis, ranging from 3 to 334 days. We conclude that IMFH associated with LR/leukocytosis does not completely respond to chemoradiation. Overproduction of growth factors and cytokines by IMFH cells and their interactions with the inflammatory infiltrate seem to promote immunological effector cell's dysfunction and substantiate the development and growth of this neoplasm. A clear understanding of these molecular pathways is crucial in order to identify targets for potential therapy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Kyriakos M, Kempson RL. Inflammatory fibrous histiocytoma, an aggressive and lethal lesion. Cancer. 1976;37(3):1584–1606. - PubMed
    1. Weiss DS, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer. 1978;41(6):2250–2266. - PubMed
    1. Oda Y, Tamiya S, Oshiro Y, et al. Reassessment and clinicopathological prognostic factors of malignant fibrous histiocytoma of soft parts. Pathology International. 2002;52(9):595–606. - PubMed
    1. Fletcher DMC. Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. American Journal of Surgical Pathology. 1992;16(3):213–228. - PubMed
    1. Murphey MD. World Health Organization classification of bone and soft tissue tumors: modifications and implications for radiologists. Seminars in Musculoskeletal Radiology. 2007;11(3):201–214. - PubMed

LinkOut - more resources